OINDPnews


Proveris Scientific

Business

Sunovion gets US rights to Utibron, Seebri, and Arcapta Neohalers

Sunovion has acquired exclusive US marketing rights to three Novartis DPIs for the treatment of COPD, the company has announced. The company said that it plans to market the Utibron (indacaterol/glycopyrrolate) Neohaler, Seebri (glycopyrrolate) Neohaler, and Arcapta (indacaterol) Neohaler beginning in 2017. Novartis will continue to manufacture the three … [Read more...] about Sunovion gets US rights to Utibron, Seebri, and Arcapta Neohalers

Capsugel to be acquired by Lonza

Lonza Group will acquire capsule manufacturer and CDMO Capsugel from KKR for $5.5 billion, the company has announced. The deal has been approved by the boards of both companies and is expected to close by mid-2017. KKR acquired Capsugel from Pfizer in 2011 for a little less than $2.4 billion. Capsugel manufactures capsules for DPIs and offers development and … [Read more...] about Capsugel to be acquired by Lonza

Startup Cephalgia gets funding from University of Chicago Innovation Fund for intranasal IGF-1

Cephalgia, a startup spun out of the University of Chicago, will receive $250,000 from the university's Innovation Fund for development of intranasal IGF-1 for the treatment of migraine, according to the fund. The company was selected to receive the money after pitching its business plan in a live competition. University of Chicago Associate VP for Entrepreneurship … [Read more...] about Startup Cephalgia gets funding from University of Chicago Innovation Fund for intranasal IGF-1

Impel NeuroPharma raises $36 million for development of intranasal CNS products

Intranasal drug developer Impel NeuroPharma has received $21 million in the initial tranche of a Series C financing round, with another $15 million available on completion of development and business milestones, the company said. Investors venBIO, 5AM Ventures and Vivo Capital, contributed equally. Impel NeuroPharma CEO John Hoekman said, “The nasal cavity is a … [Read more...] about Impel NeuroPharma raises $36 million for development of intranasal CNS products

US federal judge rules that Teva’s mometasone furoate nasal spray does not infringe on Merck’s patent

On November 14, 2016, Judge Sue Robinson of the US District Court for the District of Delaware issued a ruling upholding Merck's US patent 6,127,353 but finding that Teva's mometasone nasal spray ANDA does not infringe the claims of that patent. Merck filed suit against Teva in July 2014 after Teva submitted an ANDA for the product to the FDA. Much of the … [Read more...] about US federal judge rules that Teva’s mometasone furoate nasal spray does not infringe on Merck’s patent

Pharmaxis partners with Woolcock Institute on development of tobramycin DPI

Pharmaxis will collaborate with the Woolcock Institute of Medical Research to develop a tobramycin dry powder inhaler for the treatment of cystic fibrosis, the company has announced. A A$421,545 grant from the Australian National Health and Medical Research Council (NHMRC) will fund the research to develop a dry powder formulation for delivery by Pharmaxis's Orbital … [Read more...] about Pharmaxis partners with Woolcock Institute on development of tobramycin DPI

Sanofi and MannKind finalize agreement on return of Afrezza rights

According to MannKind Corporation, it has reached an agreement with Sanofi regarding the return of rights to Afrezza inhaled insulin, in which "All issues arising out of the license and collaboration agreement, the supply agreement, the promissory note, the security agreement and the transition agreement are resolved." In January 2016, Sanofi announced that it … [Read more...] about Sanofi and MannKind finalize agreement on return of Afrezza rights